Jeremy B. Hayden Sells 4,878 Shares of Sight Sciences, Inc. (NASDAQ:SGHT) Stock

Sight Sciences, Inc. (NASDAQ:SGHT) insider Jeremy B. Hayden sold 4,878 shares of the firm’s stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $6.08, for a total value of $29,658.24. Following the completion of the sale, the insider now directly owns 158,687 shares in the company, valued at $964,816.96. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Sight Sciences Trading Down 3.2 %

SGHT opened at $5.81 on Friday. The company has a quick ratio of 10.50, a current ratio of 11.01 and a debt-to-equity ratio of 0.33. Sight Sciences, Inc. has a 52 week low of $1.04 and a 52 week high of $8.45. The stock has a market cap of $289.08 million, a PE ratio of -5.19 and a beta of 2.71. The business has a 50 day moving average of $6.50 and a 200-day moving average of $6.23.

Sight Sciences (NASDAQ:SGHT) last announced its quarterly earnings data on Thursday, August 1st. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.06. The business had revenue of $21.37 million during the quarter, compared to analyst estimates of $21.32 million. Sight Sciences had a negative return on equity of 45.68% and a negative net margin of 65.90%. During the same quarter last year, the firm posted ($0.30) earnings per share. Equities research analysts predict that Sight Sciences, Inc. will post -1 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Sight Sciences

Hedge funds have recently bought and sold shares of the business. RTW Investments LP bought a new position in shares of Sight Sciences during the fourth quarter valued at approximately $850,000. Jacobs Levy Equity Management Inc. increased its position in Sight Sciences by 25.5% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 377,057 shares of the company’s stock valued at $1,991,000 after buying an additional 76,549 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in Sight Sciences by 51.9% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 26,653 shares of the company’s stock valued at $141,000 after buying an additional 9,106 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Sight Sciences by 5.5% in the first quarter. Vanguard Group Inc. now owns 1,556,450 shares of the company’s stock worth $8,218,000 after acquiring an additional 81,768 shares in the last quarter. Finally, Acadian Asset Management LLC grew its stake in shares of Sight Sciences by 256.6% in the second quarter. Acadian Asset Management LLC now owns 83,693 shares of the company’s stock worth $556,000 after acquiring an additional 60,220 shares during the last quarter. Institutional investors own 55.51% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on SGHT shares. Lake Street Capital started coverage on Sight Sciences in a report on Wednesday, August 21st. They issued a “buy” rating and a $10.00 price objective for the company. Citigroup raised their price target on Sight Sciences from $6.00 to $6.50 and gave the stock a “neutral” rating in a research note on Wednesday, July 10th. Needham & Company LLC reissued a “hold” rating on shares of Sight Sciences in a research report on Friday, August 2nd. Finally, Morgan Stanley raised their target price on shares of Sight Sciences from $5.40 to $6.50 and gave the stock an “equal weight” rating in a research report on Monday, July 15th. Four analysts have rated the stock with a hold rating and one has given a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $7.25.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.